Facing dwindling product pipelines and looming patent cliffs, nearly all of the world's major drugmakers have recently overhauled their research and development activities. Brendan Borrell asks what difference these efforts have made.
This is a preview of subscription content, log in via an institution to check access.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Borrell, B. Restructurally sound. Nat Med 17, 531–533 (2011). https://doi.org/10.1038/nm0511-531
Published:
Issue Date:
DOI: https://doi.org/10.1038/nm0511-531
- Springer Nature America, Inc.